Leadership & Pay ·
On June 25, 2026, Sera Prognostics, Inc. appointed Mark Capone as a Class II director and member of the Compensation…
SERASera Prognostics, Inc.
On June 25, 2026, Sera Prognostics, Inc. appointed Mark Capone as a Class II director and member of the Compensation Committee, effective July 1, 2026. Mr. Capone's initial term expires at the 2029 annual meeting. On July 10, 2026, he will receive an initial equity award of the lesser of $167,072 in fair value (split between options and RSUs) or 150,000 option equivalents. He is also eligible for annual equity awards of the lesser of $88,359 or 75,000 option equivalents. Mr. Capone is a former CEO of Myriad Genetics and currently serves as CEO of Precision Medicine Advisors, LLC. The company operates in the healthcare industry and develops molecular diagnostics and precision medicine products.